{
  "guideline": {
    "id": "PA166129519",
    "name": "Annotation of FDA Label for sevoflurane and CACNA1S, RYR1",
    "source": "FDA",
    "version": 33,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166129519",
    "relatedChemicals": [
      {
        "id": "PA451341",
        "name": "sevoflurane",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA85",
        "name": "calcium voltage-gated channel subunit alpha1 S",
        "symbol": "CACNA1S"
      },
      {
        "id": "PA34896",
        "name": "ryanodine receptor 1",
        "symbol": "RYR1"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312621",
      "name": "Recommendation Annotation PA166312621",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451341",
          "name": "sevoflurane",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452218680,
        "html": "<p>&quot;CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia...ULTANE [sevoflurane] can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "RYR1": "No Result",
        "CACNA1S": "Uncertain Susceptibility"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312601",
      "name": "Recommendation Annotation PA166312601",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451341",
          "name": "sevoflurane",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452218665,
        "html": "<p>&quot;CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia...ULTANE [sevoflurane] can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "RYR1": "Uncertain Susceptibility",
        "CACNA1S": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311901",
      "name": "Recommendation Annotation PA166311901",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451341",
          "name": "sevoflurane",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216100,
        "html": "<p>&quot;CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia...ULTANE [sevoflurane] can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "RYR1": "Malignant Hyperthermia Susceptibility",
        "CACNA1S": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311881",
      "name": "Recommendation Annotation PA166311881",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451341",
          "name": "sevoflurane",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216080,
        "html": "<p>&quot;CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia...ULTANE [sevoflurane] can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "RYR1": "Malignant Hyperthermia Susceptibility",
        "CACNA1S": "Malignant Hyperthermia Susceptibility"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311883",
      "name": "Recommendation Annotation PA166311883",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451341",
          "name": "sevoflurane",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216082,
        "html": "<p>&quot;CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia...ULTANE [sevoflurane] can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "RYR1": "Uncertain Susceptibility",
        "CACNA1S": "Malignant Hyperthermia Susceptibility"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312602",
      "name": "Recommendation Annotation PA166312602",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451341",
          "name": "sevoflurane",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452218666,
        "html": "<p>&quot;CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia...ULTANE [sevoflurane] can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "RYR1": "Uncertain Susceptibility",
        "CACNA1S": "Uncertain Susceptibility"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311902",
      "name": "Recommendation Annotation PA166311902",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451341",
          "name": "sevoflurane",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216101,
        "html": "<p>&quot;CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia...ULTANE [sevoflurane] can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "RYR1": "Malignant Hyperthermia Susceptibility",
        "CACNA1S": "Uncertain Susceptibility"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311882",
      "name": "Recommendation Annotation PA166311882",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451341",
          "name": "sevoflurane",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216081,
        "html": "<p>&quot;CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia...ULTANE [sevoflurane] can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "RYR1": "No Result",
        "CACNA1S": "Malignant Hyperthermia Susceptibility"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Ultane (Sevoflurane), NDA020478, AbbVie Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020478"
    }
  ],
  "version": "2024-02-29-20-19"
}